InMode Ltd. (NASDAQ:INMD) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its position in InMode Ltd. (NASDAQ:INMD) by 10.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 303,328 shares of the healthcare company’s stock after selling 36,800 shares during the period. Russell Investments Group Ltd.’s holdings in InMode were worth $5,066,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new stake in shares of InMode in the fourth quarter valued at about $87,000. Farther Finance Advisors LLC lifted its position in InMode by 26.2% in the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company’s stock valued at $93,000 after purchasing an additional 1,154 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new stake in InMode in the 4th quarter valued at approximately $114,000. National Bank of Canada FI boosted its holdings in InMode by 6.2% in the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company’s stock valued at $169,000 after purchasing an additional 579 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in InMode during the 4th quarter worth approximately $174,000. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Stock Performance

InMode stock opened at $15.08 on Tuesday. InMode Ltd. has a fifty-two week low of $13.68 and a fifty-two week high of $19.85. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of 6.42 and a beta of 1.96. The stock’s fifty day moving average is $17.95 and its two-hundred day moving average is $17.66.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on INMD. Jefferies Financial Group decreased their price target on InMode from $16.00 to $15.00 and set a “hold” rating on the stock in a research note on Monday. Needham & Company LLC restated a “hold” rating on shares of InMode in a research report on Wednesday, April 9th. Finally, Barclays upped their price target on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 5th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $21.25.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.